San Diego biotech Imprimis Pharmaceuticals has introduced a competitor to Turing Pharmaceuticals' $750 a capsule Daraprim.
Imprimis' $1 version is a combination of pyrimethamine along with another generic, leucovorin, a form of folic acid.
Imprimis' substitute drug is a customized formulation that can be used to treat toxoplasmosis. The formulation is not FDA-approved, thus can legally only be sold through a doctor's prescription to a specific individual. The specific ingredients are FDA-approved and the compounding operations are FDA-inspected.
Read the Tribune article